Story perspectives

Natera Shares Surge as Signatera Test Enters Phase III Trial

8/30/2025

29 3

Summary

Story summary

Natera's shares increased by 3% after its Signatera test was chosen for a Phase III trial in bladder cancer.
The trial will involve over 100 sites across the U.S. and Canada, boosting the test's clinical relevance.
CRISPR Therapeutics is progressing with therapies, including in vivo CTX310 for atherosclerotic heart disease, showing promising early results.
Beam Therapeutics is working on BEAM-101 for sickle cell disease, with initial data indicating higher fetal hemoglobin levels.

1 of 1

Story summary

Natera's shares increased by 3% after its Signatera test was chosen for a Phase III trial in bladder cancer.
The trial will involve over 100 sites across the U.S. and Canada, boosting the test's clinical relevance.
CRISPR Therapeutics is progressing with therapies, including in vivo CTX310 for atherosclerotic heart disease, showing promising early results.
Beam Therapeutics is working on BEAM-101 for sickle cell disease, with initial data indicating higher fetal hemoglobin levels.